RetroSearch Browse

Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from http://www.ncbi.nlm.nih.gov/pubmed/29650386 below:

Human papillomavirus vaccination coverage among females and males, National Health and Nutrition Examination Survey, United States, 2007-2016

. 2018 May 3;36(19):2567-2573. doi: 10.1016/j.vaccine.2018.03.083. Epub 2018 Apr 9. Human papillomavirus vaccination coverage among females and males, National Health and Nutrition Examination Survey, United States, 2007-2016

Affiliations

¹ Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329-4027, USA; Synergy America, Inc., 6340 Sugarloaf Parkway, Suite 200, Duluth, GA 30097, USA. Electronic address: Lry9@cdc.gov.
² Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329-4027, USA.

PMID: 29650386
PMCID: PMC5993427
DOI: 10.1016/j.vaccine.2018.03.083

Item in Clipboard

Human papillomavirus vaccination coverage among females and males, National Health and Nutrition Examination Survey, United States, 2007-2016

Rayleen M Lewis et al. Vaccine. 2018.

. 2018 May 3;36(19):2567-2573. doi: 10.1016/j.vaccine.2018.03.083. Epub 2018 Apr 9. Affiliations

¹ Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329-4027, USA; Synergy America, Inc., 6340 Sugarloaf Parkway, Suite 200, Duluth, GA 30097, USA. Electronic address: Lry9@cdc.gov.
² Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329-4027, USA.

PMID: 29650386
PMCID: PMC5993427
DOI: 10.1016/j.vaccine.2018.03.083

Item in Clipboard

Abstract

Background: Human papillomavirus (HPV) vaccination has been routinely recommended at age 11-12 years in the United States for females since 2006 and males since 2011. Coverage can be estimated using self/parent-reported HPV vaccination collected in the National Health and Nutrition Examination Survey (NHANES) for a wider age range than other national surveys. We assessed vaccination coverage in 2015-2016, temporal trends by age, and the validity of self/parent-reported vaccination status.

Methods: Participants aged 9-59 years completed an interview collecting demographic and vaccination information. Weighted coverage was estimated for two-year NHANES cycles by age group for 2007-2008 to 2015-2016 for females (N = 14318) and 2011-2012 to 2015-2016 for males (N = 7847). Temporal trends in coverage were assessed from 2007-2008 to 2011-2012 for females and from 2011-2012 to 2015-2016 for both sexes. Sensitivity and specificity of self/parent-reported vaccination were assessed using provider-verified vaccination records from a pilot study in 14-29 year-olds.

Results: In 2015-2016, ≥1 dose coverage among females was highest in 14-19 (54.7%) and 20-24 (56.0%) year-olds and lower in successively older age groups. Among males, ≥1 dose coverage was highest in 14-19 year-olds (39.5%) and lower at older ages. Coverage was similar in 9-13 year-old females and males. Between 2007-2008 and 2011-2012, there were increases among females younger than 30 years. Between 2011-2012 and 2015-2016, there were increases among female age groups including 20-39 year-olds; male coverage increased among ages 9-13, 14-19, and 20-24 years. Self/parent-reported receipt of ≥1 dose had a sensitivity and specificity of 87.0% and 83.3%. Performance was lower for 3 doses.

Conclusions: While overall HPV vaccination coverage remains low, it is higher in females than males, except in 9-13 year-olds. There have been increases in coverage among many age groups, but coverage has stalled in younger females. Adequate validity was demonstrated for self/parent-reported vaccination of ≥1 dose, but not 3 doses, in a pilot study.

Keywords: HPV vaccine; Human papillomavirus; National Health and Nutrition Examination Survey; Temporal trends; Vaccination coverage.

PubMed Disclaimer

Conflict of interest statement

Declarations of interest

None.

Figures
Fig. 1

Human papillomavirus vaccination coverage of…

Fig. 1

Human papillomavirus vaccination coverage of ≥1 dose by age group and survey cycle…

Fig. 1

Human papillomavirus vaccination coverage of ≥1 dose by age group and survey cycle for females (A) and males (B). Coverage estimates are weighted and based on self/parent report. ˆp for trend < 0.05 for 2007–2008 to 2011–2012; *p for trend < 0.05 for 2011–2012 to 2015–2016. Estimates with a relative standard error (RSE) between 30% and 50%: females: 2007–2008: ages 25–29, 35–39 years; 2009–2010: ages 30–34, 35–39 years; 2015–2016: ages 35–39 years; males: 2011–2012: ages 20–24, 25–29 years; 2013–2014: ages 25–29, 35–39 years; 2015–2016: ages 30–34, 35–39 years. Estimates with a RSE over 50%: females: 2011–2012: ages 30–34, 35–39 years; males: 2011–2012: ages 30–34, 35–39 years; 2013–2014: ages 30–34 years.

Fig. 2

Human papillomavirus vaccination coverage of…

Fig. 2

Human papillomavirus vaccination coverage of 3 doses by age group and survey cycle…

Fig. 2

Human papillomavirus vaccination coverage of 3 doses by age group and survey cycle for females (A) and males (B). Coverage estimates are weighted and based on self/parent report. ˆp for trend < 0.05 for 2007–2008 to 2011–2012; *p for trend < 0.05 for 2011–2012 to 2015–2016. Estimates with a relative standard error (RSE) between 30% and 50%: females: 2007–2008: ages 9–13, 14–19, 20–24, 30–34 years; 2009–2010: ages 35–39 years; 2015–2016: ages 35–39 years; males: 2011–2012: ages 20–24 years; 2013–2014: ages 20–24 years; 2015–2016: ages 20–24, 25–29 years. Estimates with a RSE over 50%: females: 2007–2008: ages 25–29, 35–39 years; 2009–2010: ages 30–34 years; 2011–2012: ages 30–34, 35–39 years; males: 2011–2012: ages 9–13, 25–29, 30–34, 35–39 years; 2013–2014: ages 25–29, 30–34, 35–39 years; 2015–2016: ages 30–34 years.